URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Share
If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit.
Investors have until July 28, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased UroGen securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Cockrell v. UroGen Pharma Ltd., et al., No. 3:25-cv-06088.
Why was UroGen Sued for Securities Fraud?
UroGen develops treatments for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. One of the Phase 3 trials for UGN-102 is named ENVISION. As alleged, UroGen stated that the ENVISION trial met its primary endpoint and that UroGen had reached 'agreement with the FDA' that the ENVISION trial would support an NDA submission.
In truth, the FDA had previously expressed significant concerns to UroGen regarding the ENVISION trial, which lacked a concurrent control arm.
The Stock Declines as the Truth is Revealed
On May 16, 2025, the FDA published a briefing document stating that it doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. FDA stated that because 'ENVISION lacked a concurrent control arm,' the primary endpoints were 'difficult to interpret' and that UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock declined $2.54 per share, or nearly 26%, from a closing price of $9.85 per share on May 15, 2025, to $7.31 per share on May 16, 2025.
Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk profile of UGN-102 was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock declined $3.37 per share, or nearly 45%, from a closing price of $7.54 per share on May 20, 2025, to $4.17 per share on May 21, 2025.
Click here if you suffered losses: .
What Can You Do?
If you invested in UroGen you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent sevabertinib (BAY 2927088) is an oral, small molecule, tyrosine kinase inhibitor (TKI) being evaluated as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations. The U.S. Food and Drug Administration (FDA) grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. WHIPPANY, N.J., May 28, 2025--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy. "Patients with HER2-mutant NSCLC are predominantly women, may be of younger age and non-smokers. The FDA's decision to grant Priority Review designation to our application for sevabertinib is a significant milestone that supports our ongoing efforts to develop healthcare solutions that help people living with lung cancer," said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. "If approved, sevabertinib will provide an additional treatment option for previously treated patients with advanced NSCLC harboring a HER2-activating mutation." The NDA for sevabertinib is based on positive results from the ongoing Phase I/II SOHO-01 trial. Results from patients with advanced NSCLC harboring a HER2-activating mutation, who experienced disease progression after ≥1 systemic therapies for advanced disease and were naïve to HER2-targeted therapy.1 The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.2 In 2024, the FDA granted sevabertinib Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. The Breakthrough Therapy designation was supported by preliminary clinical evidence from the SOHO-01 trial. The FDA grants Breakthrough Therapy designation for the evaluation of investigational medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).3 About sevabertinib (BAY 2927088)4Sevabertinib is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is currently being evaluated as a potential new targeted treatment option for patients with NSCLC harboring human epidermal growth factor receptors 2 (HER2) activating mutations. Sevabertinib is also being studied in patients with metastatic or unresectable solid tumors harboring HER2-activating mutations. Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR. Investigational agent sevabertinib is derived from Bayer's strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA. About Non-Small Cell Lung Cancer (NSCLC)Lung cancer is the leading cause of cancer-related deaths in the U.S.5 Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for more than 85% of cases.4 Activating HER2 mutations are found in 2% to 4% of advanced NSCLC.6 80% of people diagnosed with NSCLC have already progressed to advanced stages, which makes it more difficult to treat.7 Patients with HER2-mutant NSCLC currently face limited targeted therapies.8 About Oncology at BayerBayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes several marketed products across diverse indications and multiple compounds in different stages of clinical development. We have a wealth of expertise in areas including Tumor Cell Intrinsic Pathways, Targeted Radionuclide Therapies, and selective Next-Generation Immuno-Oncology. With our portfolio we are advancing cancer treatments from early to metastatic stage, with the goal of extending survival while limiting side effects for the cancer patients we serve. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to © 2025 BayerBAYER and the Bayer Cross are registered trademarks of Bayer. Find more information at Our online press service is just a click away: Follow us on Facebook: Follow us on X: Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References Le X, et al. Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: expansion cohort from the phase I/II SOHO-01 study. Presented at the 2024 IASLC World Conference on Lung Cancer; San Diego, CA, September 7-10, 2024. PL04.03. U.S. Food and Drug Administration. "Priority Review." Accessed April 21, 2025. U.S. Food and Drug Administration. "Breakthrough Therapy." Accessed April 21, 2025. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2). Clinical trial registration No. NCT05099172. Accessed April 21, 2025. American Cancer Society. Key Statistics for Lung Cancer. Accessed April 21, 2025. Nützinger, J, et al. (2023). Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung cancer (Amsterdam, Netherlands), 186, 107385. Yale Medicine. "Non-Small Cell Lung Cancer." Accessed April 21, 2025. Uy NF,et al. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies. Cancers (Basel). 2022 Aug 27;14(17):4155. doi: 10.3390/cancers14174155. PMID: 36077691; PMCID: PMC9454740. View source version on Contacts Media Contact: Polina Miklush, Tel +1 862.431.8817Email:
Yahoo
32 minutes ago
- Yahoo
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Business Insider
an hour ago
- Business Insider
Upcoming Stock Splits This Week (June 2 to June 6)
These are the upcoming stock splits for the week of June 2 to June 6, based on TipRanks' Stock Splits Calendar. A stock split is corporate move that increases the number of outstanding shares by distributing additional shares to existing shareholders, all without affecting the company's total market value. This typically results in a lower share price, making the stock more accessible, and potentially more attractive, to retail investors. Confident Investing Starts Here: While traditional stock splits aim to broaden appeal by lowering share prices, some companies take the opposite approach. A reverse stock split consolidates shares instead of dividing them, reducing the total count while raising the price per share. The overall market value remains unchanged, but the move is often used to comply with exchange listing requirements, such as Nasdaq's minimum price rule, and prevent delisting. Strategic actions like these, whether to draw in investors or stay listed, often offer signals that savvy traders pay attention to. Let's take a look at the upcoming stock splits for the week. ARB IOT Group (ARBB) – Singapore-based ARB IOT Group provides integrated Internet of Things (IoT) solutions, including smart buildings, industrial automation, and connected agriculture systems. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's minimum bid price requirement. The split is set to take effect on June 2. Lyell Immunopharma (LYEL) – Lyell Immunopharma is a clinical-stage biotech company developing T-cell reprogramming therapies for solid tumors. On May 29, the company announced a 1-for-20 reverse stock split as part of its effort to stay in line with Nasdaq's listing requirements. The split takes effect on June 2. Applied DNA Sciences (APDN) – Applied DNA Sciences develops and commercializes DNA-based technologies for therapeutic manufacturing, diagnostics, and supply chain security. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's continued listing standards. The split is set to take effect on June 2. Mullen Automotive (MULN) – California-based Mullen Automotive, known for its electric vehicles and battery tech, announced a 1-for-100 reverse stock split on May 29 in a bid to maintain its Nasdaq listing. The split, set to take effect on June 2, is part of the company's effort to meet minimum share price requirements and stay in compliance. Ekso Bionics (EKSO) – Ekso Bionics develops wearable robotic exoskeletons to enhance mobility for people with physical limitations and for industrial use. On May 21, EKSO announced a 1-for-15 reverse stock split to restore compliance with Nasdaq's minimum price rule. The split will take effect on June 2. AGM Group Holdings (AGMH) – AGM Group provides financial technology solutions and manufactures cryptocurrency mining equipment. On May 29, the company announced a 1-for-50 reverse stock split to meet Nasdaq listing criteria. The split will be effective on June 3. ClearOne (CLRO) – ClearOne designs and sells audio-visual communications equipment including microphones, conferencing systems, and network media streaming solutions. On May 21, the company announced a 1-for-15 reverse stock split to regain Nasdaq compliance. The split will be effective on June 2, with trading on a split-adjusted basis starting June 3. Oragenics (OGEN) – Oragenics is a biotechnology company focused on developing novel antibiotics and other treatments for infectious diseases. On May 28, the company announced a 1-for-30 reverse stock split to meet NYSE American listing standards. The split will be effective on June 3.
